{"id":2390,"date":"2014-10-18T12:51:46","date_gmt":"2014-10-18T12:51:46","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2390"},"modified":"2014-10-18T12:51:46","modified_gmt":"2014-10-18T12:51:46","slug":"neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/","title":{"rendered":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?"},"content":{"rendered":"<p>AMB 2014, 48, 71 Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? Prof. Dr. E.F. aus P. schreibt (stark gek\u00fcrzt): &gt;&gt; Die Ergebnisse der Metaanalyse von C.T. Ruff et al. (1) zur Verordnung der neuen oralen Antikoagulanzien (NOAK) bei Vorhofflimmern werden in Tab.\u00a03 Ihres Artikels (2) hervorragend in die Praxis \u00fcbersetzt. Daneben sollte aber auch die 2012 [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2014, 48, 71 Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? Prof. Dr. E.F. aus P. schreibt (stark gek\u00fcrzt): &gt;&gt; Die Ergebnisse der Metaanalyse von C.T. Ruff et al. (1) zur Verordnung der neuen oralen Antikoagulanzien (NOAK) bei Vorhofflimmern werden in Tab.\u00a03 Ihres Artikels (2) hervorragend in die Praxis \u00fcbersetzt. Daneben sollte aber auch die 2012 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[200,66,127,69,720,1459,1460,1457,1458,1461,126,203,612,1462,204,205],"class_list":["post-2390","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-apixaban","tag-dabigatran","tag-edoxaban","tag-leserbrief","tag-neue","tag-neue-orale-antikoagulanzien","tag-noak","tag-orale","tag-rivaroxaban","tag-thromboembolie","tag-thrombose","tag-vitamin-k-antagonisten","tag-vorhofflimmern","tag-warfarin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?<\/title>\n<meta name=\"description\" content=\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?\" \/>\n<meta property=\"og:description\" content=\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-18T12:51:46+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?\",\"datePublished\":\"2014-10-18T12:51:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/\"},\"wordCount\":547,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Absolute Arrhythmie\",\"Antikoagulanzien\",\"Apixaban\",\"Dabigatran\",\"Edoxaban\",\"Leserbrief\",\"Neue\",\"Neue orale Antikoagulanzien\",\"NOAK\",\"orale\",\"Rivaroxaban\",\"Thromboembolie\",\"Thrombose\",\"Vitamin-K-Antagonisten\",\"Vorhofflimmern\",\"Warfarin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/\",\"name\":\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-10-18T12:51:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?","description":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/","og_locale":"de_DE","og_type":"article","og_title":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?","og_description":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-10-18T12:51:46+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?","datePublished":"2014-10-18T12:51:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/"},"wordCount":547,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Absolute Arrhythmie","Antikoagulanzien","Apixaban","Dabigatran","Edoxaban","Leserbrief","Neue","Neue orale Antikoagulanzien","NOAK","orale","Rivaroxaban","Thromboembolie","Thrombose","Vitamin-K-Antagonisten","Vorhofflimmern","Warfarin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/","name":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-10-18T12:51:46+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten? UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neue-orale-antikoagulanzien-oder-vitamin-k-antagonisten\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Leserbrief: Neue orale Antikoagulanzien oder Vitamin-K-Antagonisten?"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2390"}],"version-history":[{"count":5,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2390\/revisions"}],"predecessor-version":[{"id":2395,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2390\/revisions\/2395"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}